Skip to main content

Table 2 Univariate and multivariate analysis of overall survival based on clinical and molecular variables

From: Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Variable

Univariate analysis

Multivariate analysis

Crude HR

95%CI

P

Adjusted HR

95%CI

P

Age

1.02

1.00ā€“1.03

0.02

1.01

1.00ā€“1.03

0.07

Sex

ā€ƒFemale

1

Ā Ā 

1

Ā Ā 

ā€ƒMale

1.41

1.05ā€“1.90

0.02

1.08

0.74ā€“1.58

0.71

Ever Smoking

ā€ƒNon-smoker

1

Ā Ā 

1

Ā Ā 

ā€ƒSmoker

1.46

1.13ā€“1.90

0.004

1.39

1.00ā€“1.94

0.05

Pathology

ā€ƒAdenocarcinoma

1

Ā Ā Ā Ā Ā 

ā€ƒSquamous carcinoma

1.16

0.71ā€“1.88

0.55

Ā Ā Ā 

ā€ƒothers

1.14

0.64ā€“2.06

0.65

Ā Ā Ā 

Stage

ā€ƒI-II

1

Ā Ā 

1

Ā Ā 

ā€ƒIII

1.55

0.88ā€“2.74

0.13

1.58

0.89ā€“2.81

0.12

ā€ƒIV

2.68

1.60ā€“4.47

***

2.72

1.62ā€“4.56

***

KRAS mutation

ā€ƒWildtype

1

Ā Ā 

1

Ā Ā 

ā€ƒMutation

1.51

1.16ā€“1.98

0.003

1.30

0.98ā€“1.72

0.07

KRAS mutation subtype

ā€ƒWild-type

1

Ā Ā 

1

Ā Ā 

G12C mutation

1.65

1.10ā€“2.47

0.02

1.47

0.97ā€“2.23

0.07

ā€ƒNon-G12C mutation

1.45

1.06ā€“1.98

0.02

1.23

0.90ā€“1.69

0.20

  1. NSCLC non-small cell lung cancer, HR hazard ratio